Archive for April, 2012
We’ve recently added functionality allowing users to import their flow cytometry data directly from their core facility to Cytobank for storage and analysis. The initial phase of this effort is a collaboration between Cytobank and the Stanford University Shared FACS Facility, where researchers can now directly import their data collected at the facility into Cytobank.
For Stanford users, there are two ways to import your data to Cytobank. One is a “Cytobank” link at the bottom of the email users receive after collecting their data. A user can also initiate data import from the FACS facility by going to http://facs.stanford.edu and clicking on the “Data Archive” link.
Welcome to Cytobank User Stories, a series featuring interviews with Cytobank users on their research, scientific vision, and use of flow cytometry.
This time we interview Joshua Brody, M.D., Director of the Lymphoma Immunotherapy Program at Mount Sinai School of Medicine. Joshua’s recent publications include his studies showing that in situ vaccination with a TLR9 agonist induces systemic anti-lymphoma clinical responses, as well as his studies using immunotransplant to preferrentially expand T-effector cells to cure large lymphoma tumors.
Send us feedback and let us know who you’d like to hear from (including yourself)!
|What are you excited about in science? What is your scientific vision?|
I’m excited about the fact that FINALLY we are really learning how to use the immune system to make cancers shrink and let patients live longer. For years, tumor immunologists and ‘immunotherapists’ have thought: ”This should work. We should be able to make this work!”, but every year our understanding of the complexity of the immune system has become clearer. Finally, that understanding is being translated into therapies that help patients with cancer. We have seen it with melanoma and prostate cancer in the past 2 years and we clearly see even more powerful therapies on the near-horizon.|